/ANTH
ANTH Stock - Anthera Pharmaceuticals, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-123.12
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | N/A | $145,000 | $3.19M | N/A | N/A |
| Gross Profit | $-281,000 | $98,749 | $3.15M | $-21,839 | $-21,684 |
| Gross Margin | N/A | 68.1% | 99.0% | N/A | N/A |
| Operating Income | $-36,432,000 | $-57,177,000 | $-35,243,000 | $-28,459,000 | $-28,247,000 |
| Net Income | $-16,935,000 | $-53,603,000 | $-34,912,000 | $-30,309,000 | $-33,107,000 |
| Net Margin | N/A | -36967.6% | -1096.1% | N/A | N/A |
| EPS | $-1.65 | $-10.38 | $-7.84 | $-11.13 | $-14.50 |
Company Overview
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ANTHBeat Rate
68%
Last 19 quarters
Avg Surprise
+8.1%
EPS vs Estimate
Beats / Misses
13/5
1 met exactly
Latest EPS
$-0.42
Q2 2018
EPS Surprise History
Q3 16
-12.9%
$-2.80vs$-2.48
Q4 16
-74.3%
$-4.88vs$-2.80
Q1 17
+12.2%
$-2.88vs$-3.28
Q2 17
-46.0%
$-2.03vs$-1.39
Q3 17
+20.4%
$-0.86vs$-1.08
Q4 17
+35.6%
$-0.58vs$-0.90
Q1 18
-2.8%
$-0.73vs$-0.71
Q2 18
+30.0%
$-0.42vs$-0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2018 | Sep 17, 2018 | — | — | — | — |
Q2 2018 | May 15, 2018 | $-0.60 | $-0.42 | +30.0% | ✓ BEAT |
Q1 2018 | Mar 5, 2018 | $-0.71 | $-0.73 | -2.8% | ✗ MISS |
Q4 2017 | Nov 6, 2017 | $-0.90 | $-0.58 | +35.6% | ✓ BEAT |
Q3 2017 | Aug 9, 2017 | $-1.08 | $-0.86 | +20.4% | ✓ BEAT |
Q2 2017 | May 10, 2017 | $-1.39 | $-2.03 | -46.0% | ✗ MISS |
Q1 2017 | Feb 27, 2017 | $-3.28 | $-2.88 | +12.2% | ✓ BEAT |
Q4 2016 | Nov 4, 2016 | $-2.80 | $-4.88 | -74.3% | ✗ MISS |
Q3 2016 | Aug 9, 2016 | $-2.48 | $-2.80 | -12.9% | ✗ MISS |
Q2 2016 | May 9, 2016 | $-2.32 | $-2.32 | 0.0% | = MET |
Q1 2016 | Mar 10, 2016 | $-2.24 | $-1.44 | +35.7% | ✓ BEAT |
Q4 2015 | Nov 6, 2015 | $-2.08 | $-2.32 | -11.5% | ✗ MISS |
Q3 2015 | Aug 10, 2015 | $-2.24 | $-2.00 | +10.7% | ✓ BEAT |
Q2 2015 | May 11, 2015 | $-2.48 | $-2.24 | +9.7% | ✓ BEAT |
Q1 2015 | Mar 16, 2015 | $-2.64 | $-2.56 | +3.0% | ✓ BEAT |
Q4 2014 | Nov 14, 2014 | $-2.88 | $-2.48 | +13.9% | ✓ BEAT |
Q3 2014 | Jul 28, 2014 | $-4.08 | $-2.72 | +33.3% | ✓ BEAT |
Q2 2014 | May 13, 2014 | $-4.48 | $-3.12 | +30.4% | ✓ BEAT |
Q1 2014 | Mar 12, 2014 | $-4.40 | $-3.84 | +12.7% | ✓ BEAT |
Q4 2013 | Oct 29, 2013 | $-5.20 | $-2.40 | +53.8% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ANTH
What is ANTH's current stock price?
Anthera Pharmaceuticals, Inc. (ANTH) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for ANTH?
No analyst price targets are currently available for this stock.
What sector is Anthera Pharmaceuticals, Inc. in?
Anthera Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ANTH's market cap?
Anthera Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ANTH pay dividends?
No, Anthera Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCMRA
Comera Life Sciences Holdings, Inc.
$0.00
Mkt Cap: $0.0B
COTQF
Cotinga Pharmaceuticals Inc.
$0.00
Mkt Cap: $0.0B
GBIM
GlobeImmune, Inc.
$0.00
Mkt Cap: $0.0B
NTII
Neurobiological Technologies, Inc.
$0.00
Mkt Cap: $0.0B
OVIT
OncoVista Innovative Therapies, Inc.
$0.00
Mkt Cap: $0.0B
PZRXQ
PhaseRx, Inc.
$0.00
Mkt Cap: $0.0B
SNNAQ
Sienna Biopharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
SVSO
SheerVision, Inc.
$0.00
Mkt Cap: $0.0B
SYVC
Synovics Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
VHAQ
Viveon Health Acquisition Corp.
$10.00
Mkt Cap: $0.1B
Explore stocks similar to ANTH for comparison